Novo Nordisk A/S (NYSE:NVO) Shares Bought by Stablepoint Partners LLC

Stablepoint Partners LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 55.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 18,798 shares of the company’s stock after acquiring an additional 6,730 shares during the quarter. Stablepoint Partners LLC’s holdings in Novo Nordisk A/S were worth $1,305,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. GQG Partners LLC lifted its position in shares of Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after buying an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Novo Nordisk A/S during the fourth quarter worth about $404,910,000. Loomis Sayles & Co. L P lifted its holdings in Novo Nordisk A/S by 34.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after acquiring an additional 2,947,771 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in Novo Nordisk A/S by 73.2% in the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock valued at $537,189,000 after acquiring an additional 2,639,693 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $158,657,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Up 2.8%

NYSE:NVO opened at $74.70 on Friday. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The business has a fifty day moving average of $65.87 and a 200-day moving average of $80.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a market cap of $335.22 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 0.90 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The firm had revenue of $11.87 billion during the quarter. Equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on NVO shares. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $128.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.